Domenico Coppola
It has been demonstrated that Patient-Derived Organoids (PDOs) and Patient-Derived Xenografts (PDXs) can simulate the clinical response to cancer treatment. Utilizing these models to help prompt clinical decisions for cancer patients is still difficult. Here, we combined temperature control, dead-volume minimization, and droplet emulsion microfluidics to quickly produce thousands of micro-organ spheres (MOSs) from low-volume patient tissues, which serve as the perfect patient-derived model for clinical precision oncology. Using a MOSbased precision oncology pipeline, a clinical investigation of patients with recently diagnosed advanced Colorectal Cancer (CRC) accurately assessed tumor medication response within 14 days, a time frame adequate for directing treatment decisions in the clinic. Additionally, MOSs isolate the original stromal cells and permit T cell penetration offers a clinical assay enabling PD-1 blockade, bispecific antibodies, and other Immuno-Oncology (IO) treatments to be tested on patient malignancies